Chang Tse-Shao, Feng Shuo, Li Gaoming, Li Haijun, Wu Xiaoli, Jaiswal Sangeeta, Xu Guan, Jiang Hui, Choi Eun-Young K, Oldham Kenn R, Wang Thomas D
Department of Mechanical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Biosens Bioelectron. 2025 Nov 15;288:117757. doi: 10.1016/j.bios.2025.117757. Epub 2025 Jul 4.
Accurate in vivo staging of early gastrointestinal (GI) cancers is critical for selecting between local and systemic therapy. We present a molecularly targeted photoacoustic endoscopy (PAE) system that combines a compact, fiber-scanning side-view probe with a HER2-targeted near-infrared (NIR) contrast agent (KSP∗-IRDye800) to assess mucosal and submucosal tumor invasion in vivo. The 4.2 mm diameter probe uses a piezoelectric (PZT) bender to steer a laser beam laterally (±16°) and achieve high-resolution imaging. The system provides 363 μm lateral and 119 μm axial resolution at a depth of 3.1 mm and supports 3D volumetric image acquisition via rotational scanning and linear pullback. In vivo imaging was performed in CPC;Apc mice that spontaneously develop colonic adenomas. The targeted contrast agent demonstrated a significantly higher peak target-to-background (T/B) ratio (3.0 ± 0.3, RSD = 10 %) than indocyanine green (ICG, 1.37 ± 0.1), with peak uptake at 1.5 h post-injection. Adenoma dimensions measured by PAE correlated strongly with histology (ρ = 0.97 for width, ρ = 0.90 for depth), and 3D reconstructions accurately delineated tumor margins. Ex vivo validation confirmed imaging performance and molecular specificity. This work demonstrates the feasibility of targeted PAE for high-resolution, minimally invasive staging of early GI tumors. The system's resolution and depth performance are sufficient to distinguish between T1 and T1 lesions. Integration of molecular contrast with miniaturized photoacoustic imaging enables real-time assessment of tumor invasion depth and has potential to improve diagnostic accuracy and therapeutic decision-making during endoscopy.
早期胃肠道(GI)癌的准确体内分期对于选择局部治疗还是全身治疗至关重要。我们展示了一种分子靶向光声内镜(PAE)系统,该系统将紧凑型光纤扫描侧视探头与HER2靶向近红外(NIR)造影剂(KSP∗-IRDye800)相结合,以在体内评估黏膜和黏膜下肿瘤浸润情况。直径4.2毫米的探头使用压电(PZT)弯曲器横向操纵激光束(±16°),从而实现高分辨率成像。该系统在3.1毫米深度处提供363微米的横向分辨率和119微米的轴向分辨率,并支持通过旋转扫描和线性回拉进行三维容积图像采集。在自发发生结肠腺瘤的CPC;Apc小鼠中进行了体内成像。靶向造影剂显示出比吲哚菁绿(ICG,1.37±0.1)显著更高的峰值靶本底(T/B)比(3.0±0.3,相对标准偏差=10%),在注射后1.5小时达到峰值摄取。通过PAE测量的腺瘤尺寸与组织学密切相关(宽度的ρ=0.97,深度的ρ=0.90),并且三维重建准确描绘了肿瘤边缘。离体验证证实了成像性能和分子特异性。这项工作证明了靶向PAE用于早期胃肠道肿瘤高分辨率、微创分期的可行性。该系统的分辨率和深度性能足以区分T1和T1期病变。分子造影与小型化光声成像的整合能够实时评估肿瘤浸润深度,并且有潜力提高内镜检查期间的诊断准确性和治疗决策水平。